Skip to Content


Active substance(s): TRANEXAMIC ACID

PDF options:  View Fullscreen   Download PDF

PDF Transcript

inks on file

Process structure

Package leaflet: Information for the user

Cyklokapron® 500mg Solution for Injection

tranexamic acid


Read all of this leaflet carefully before you are given this medicine because it contains
important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not
listed in this leaflet. See section 4.
What is in this leaflet
1. What Cyklokapron is and what it is used for
2. What you need to know before you are given Cyklokapron
3. How to take Cyklokapron
4. Possible side effects
5. How to store Cyklokapron
6. Contents of the pack and other information
1. What Cyklokapron is and what it is used for
Cyklokapron contains tranexamic acid which belongs to a group of medicines called antihaemorragics;
antifibrinolitics, aminoacids.
Cyklokapron is used in adults and children above one year of age for the prevention and treatment of
bleeding due to a process that inhibits blood clotting called fibrinolysis.
Specific indications include:
- Heavy periods in women
- Gastrointestinal bleeding
- Haemorrhagic urinary disorders, further to prostate surgery or surgical procedures affecting the
urinary tract
- Ear, nose or throat surgery
• heart, abdominal or gynaecological surgery
• bleeding after you have been treated with another medicine to break down blood clots.
2. What you need to know before you are given Cyklokapron
Do not take Cyklokapron:
• If you are allergic to tranexamic acid or any of the other ingredients of this medicine (listed in section 6)
• If you have currently a disease leading to blood clots
• If you have a condition called ‘consumption coagulopathy’ where blood in the whole body starts to clot
• If you have kidney problems
• If you have a history of convulsions

Process Black

Due to the risk of cerebral oedema and convulsions, intrathecal and intraventricular injection and
intracerebral application are not recommended.
If you think any of these apply to you, or if you are in any doubt at all, tell your doctor before taking
Warnings and precautions
Talk to your doctor or nurse if any of these apply to you to help him or her decide if Cyklokapron is
suitable for you:
• If you have had blood in your urine, it may lead to urinary tract obstruction.
• If you have a risk of having blood clots.
• If you have excessive clotting or bleeding throughout your body (disseminated intravascular
coagulation), Cyklokapron may not be right for you, except if you have acute severe bleeding and
blood tests have shown the process that inhibits blood clotting called fibrinolysis is activated.
• If you have had convulsions, Cyklokapron should not be administered. Your doctor must use the
minimal dose possible to avoid convulsions following treatment with Cyklokapron.
• If you are on a long-term treatment with Cyklokapron Solution for Injection, attention should be paid
to possible disturbances of colour vision and if necessary the treatment should be discontinued. With
continuous long-term use of Cyklokapron, regular ophthalmologic examinations (eye examinations
including visual acuity, colour vision, fundus, visual field etc.) are indicated. With pathological
ophthalmic changes, particularly with diseases of the retina, your doctor must take a decision after
consulting a specialist on the necessity for the long-term use of Cyklokapron in your case.
Other medicines and Cyklokapron
Tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other
You should specifically tell them if you take:
• other medicines that help blood to clot called antifibrinolytic medicines
• medicines that prevent blood clotting, called thrombolytic medicines
• oral contraceptives
Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your
doctor or pharmacist for advice before taking this medicine. Tranexamic acid is excreted in human milk.
Therefore, the use of Cyklokapron during breast-feeding is not recommended.
Driving and using machines
No studies have been performed on the ability to drive and use machines.

3. How to use Cyklokapron


Cyklokapron solution for injection will be given to you by slow injection into a vein.
Your doctor will decide the correct dose for you and how long you should take it.
Use in children
If Cyklokapron solution for injection is given to a child from one year, the dose will be based on the child’s
Your doctor will decide the correct dose for the child and how long he/she should take it.
Use in elderly
No reduction in dosage is necessary unless there is evidence of renal failure.
Use in patients with kidney problem
If you have a kidney problem, your dose of tranexamic acid will be reduced according to a test performed
on your blood (serum creatinine level).
Use in patients with hepatic impairment
No reduction in dosage is necessary.
Method of administration
Cyklokapron should only be administered slowly into a vein.
Cyklokapron must not be injected into a muscle.
If you are given more Cyklokapron than the recommended dose
If you are given more Cyklokapron than the recommended dose you may experience a transitory blood
pressure lowering. Talk to a doctor or pharmacist immediately.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Side effects reported with Cyklokapron are:
The following side effects have been observed with Cyklokapron
Common: may affect up to 1 in 10 people
• effects on the stomach and intestines: nausea, vomiting, diarrhoea
Uncommon: may affect up to 1 in 100 people
• effects on the skin problems: rash
Not known: frequency cannot be estimated from the available data
• malaise with hypotension (low blood pressure), especially if the injection is given too quickly
• blood clots
• effects on the nervous system: convulsions
• effects on the eyes: vision disturbances including impaired colour vision
• effects on the immune system: allergic reactions
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows
continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions via the Yellow Card Scheme website:
5. How to store Cyklokapron
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and ampoule label after EXP.
The expiry date refers to the last day of that month.
Do not freeze.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw
away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Cyklokapron contains
The active substance is tranexamic acid.
Each 5 ml of the solution contains 500 mg of tranexamic acid.
The other ingredient is water for injections.
What Cyklokapron looks like and contents of the pack
Cyklokapron is a solution for injection in glass ampoules containing 500 mg in 5 ml solution.
Packs with 5, 6 or 10 Type I glass 5 mL ampoules in an outer carton, each ampoule containing 500 mg
tranexamic acid.
Packs with 10 x 1 Type I glass 5 mL ampoules in an outer carton, each ampoule containing 500 mg
tranexamic acid.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer:
Marketing Authorisation Holder:
Pfizer Limited
Ramsgate Road
Sandwich, Kent
CT13 9NJ
Pfizer Manufacturing Belgium NV
Rijksweg 12
B-2870 PUURS

Process Black

Company contact address:
For further information on your medicine contact Medical Information at the following address:
Pfizer Limited, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS
Telephone 01304 616161
This leaflet was last revised in: 12/2015
Ref: CK 7_2


+ Expand Transcript

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.